Navigation Links
TriLink Awarded SBIR Phase I Grant: Thermally Activatable Probes and Cofactors for Hot Start Ligase Chain Reaction
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- TriLink BioTechnologies, Inc. (TriLink) was recently awarded a Phase I SBIR Grant of approximately $100,000 by the National Institutes of Health to develop a Hot Start approach for Ligase Chain Reaction (LCR). Hot Start LCR will employ chemically modified ligation components containing thermolabile protecting groups to eliminate common performance problems seen in LCR, such as false-positive signals and non-specificity. TriLink hopes to find similar benefits as those found in development of their Hot Start primers and dNTPs. If successful, this approach could allow LCR to replace applications where traditional PCR, Gap-LCR and PCR/ligation combination approaches are too expensive, not applicable or problematic. This is the fifth Phase I grant TriLink has been awarded, and it will be funded through July 2011.

"We are excited to have the opportunity to test our proven Hot Start approach on an application with the potential to capture a significant portion of the PCR market," remarked Dr. Alexandre Lebedev, Senior Principal Scientist.

"Moving into LCR is a natural progression for TriLink. While developing our successful CleanAmp™ PCR products and our ongoing ligation work, we gained a unique perspective on the limitations of LCR, and the technical knowledge to solve them," stated TriLink's President and CEO, Richard Hogrefe.

About TriLink

TriLink manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp™ PCR products for the research, diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered.  TriLink's solutions help advance drug discovery and biomedical research.  Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 85 scientists and other professionals. For more information about the firm and products, call 858-546-0004, email info@trilinkbiotech.com, or visit our web site at www.trilinkbiotech.com.


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
2. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
3. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
4. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
5. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
6. 6th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Beatrice Mintz, Ph.D.
7. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
8. Omni Bio Pharmaceutical Awarded Patent for Preventing Anthrax Infection
9. Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program
10. Georgia Techs Walt de Heer awarded Materials Research Society Medal
11. Sigma® Life Science Awarded Silver in Top Ten Innovations 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a ... its financial results for the fourth quarter and fiscal year ... Total sales in the fourth quarter ... by 13.6% in USD terms to $77.6 million from $68.3 ... Gross profit increased by 13.3% to $46.8 million from $41.3 ...
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
Breaking Biology Technology:
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):